Short Interest & Thesis

Short Interest and Thesis — Sonova Holding AG (SOON)

Bottom line. For this SIX-listed Swiss name, there is no decision-useful short-positioning data: no official/public reported short interest, no daily short-sale-volume feed, no public net-short (threshold) disclosures, no borrow/securities-lending indicators, and no peer short-interest comparison were staged, and no credible public short-seller report or activist campaign surfaced. The only positioning-adjacent signal is a cautious sell-side consensus (staged estimate data), and the only substantive "thesis risk" is disclosed in Sonova's own accounts: FY2025/26 net income fell to CHF 439.4 million from CHF 547.0 million, driven almost entirely by a CHF 106.5 million loss on the Consumer Hearing business now classified as held-for-sale, cutting diluted EPS to CHF 7.22 [1]. Crucially, that headline weakness is largely non-operational — continuing-operations sales still grew 5.9% in local currencies (down only 0.2% in Swiss francs on FX) [2] — so the bear case rests on a divestiture drag and FX, not a collapse in the underlying franchise. Short interest is not a driver of the SOON setup; read this page as thesis-risk, not positioning.

Evidence availability — what exists, what does not

The short-interest data step returned status: partial / reported short interest unavailable for SOON: zero reported-short-interest rows, zero short-sale-volume rows, zero public net-short disclosure rows, zero borrow rows, and zero peer rows. The staging note is explicit: "No deterministic official/public short-interest fetcher is configured for this market (SIX) in v1," and ADV-based days-to-cover therefore cannot be computed from a reported short position. Switzerland has no FINRA-style semi-monthly consolidated short-interest print, and no holder crossed a Swiss net-short threshold on file. This is a genuine data gap, stated up front rather than papered over with trading-flow volume.

What a short thesis would have to lean on (grounded in disclosures)

With no positioning data, the only honest way to assess thesis risk is against Sonova's own primary record. The ledger below separates the bear argument, the company disclosure/response, and the unresolved risk — each anchored to the filing page.

Sources, all from Sonova's FY2025/26 report: divestiture and continuing-operations growth [3]; income statement [4]; OTC/regulatory scope [5]; buyback program [6].

The single most important framing point for a PM: the FY26 earnings decline is a reclassification-and-FX story, not an operating collapse. Net income from continuing operations was roughly flat at CHF 546.0 million (FY25: CHF 564.9 million); the entire step-down to CHF 439.4 million is the CHF 106.5 million discontinued-operations loss on Consumer Hearing [7]. A short leaning on the headline EPS drop of 20.3% [8] is largely selling the divestiture optics.

Source: FY2025/26 consolidated income statement — continuing income of CHF 546.0m against a CHF 106.5m discontinued-operations loss [9].

Continuing profit is stable; the red bar is the whole story. That asymmetry matters for the setup: a clean disposal of Consumer Hearing removes the drag rather than confirming a bear thesis.

Crowding vs liquidity (proxy only — no short number to crowd)

Because no short position is reported, crowding cannot be measured — there is no shares-short, no percent-of-float, and no days-to-cover. What can be framed is the liquidity backdrop a hypothetical short would face. SOON trades roughly 168,000 shares a day (about CHF 33 million of turnover) against a market capitalization near CHF 12.5 billion, with net debt of about CHF 634 million — an ample, liquid large-cap, not a thin borrow-constrained micro-cap.

Sources: price and turnover derived from the staged daily price feed (as reported); net debt derived from the consolidated balance sheet — cash and equivalents of CHF 721.9m against CHF 1,355.5m non-current financial liabilities [10].

Free float is the one structural nuance. Founder-linked anchors hold roughly 17% of the register — the Diethelm holding at 11.26% and the Rihs family at 6.18% — with BlackRock and UBS fund vehicles each above 5% [11]. That leaves an estimated ~82% free float: not tight enough to manufacture a squeeze, but a reminder that a fifth of the register is effectively strategic and not lending-motivated.

Source: FY2025/26 disclosed holders above 3% — Diethelm 11.26%, Rihs 6.18%, UBS 5.48%, BlackRock 5.10% [12].

On the supply side, the company itself held only 222,207 treasury shares at 31 March 2026 (up from 18,825) [13], and the CHF 1.5 billion 2022–2025 buyback — historically a share-count reducer via capital cancellation, not a dilution source — ended on 18 April 2025 with no repurchases during FY2025/26 [14]. There is no dilution overhang for a short to press; if anything, the removed buyback bid is a mild negative for the long side, not a short catalyst.

Market setup — cautious sell-side is the only positioning proxy

With no measured short interest, the nearest read on "the market being offside" is analyst positioning, and it leans cautious. Staged consensus (source: staged estimate data, claude_web) shows a Hold that tilts to sell — one aggregator counts 9 sell plus 3 strong-sell against just 2 strong-buy and 3 buy out of 28 analysts, and TipRanks labels it "Moderate Sell." Yet the mean target (~CHF 229–239) sits above the ~CHF 209 share price, so the caution is on momentum, not on a crash. Next earnings land on 12 November 2026.

Source: staged estimate data (analyst ratings aggregated from public trackers); not a reported short position and not a PDF-citable filing.

This distribution is the closest thing SOON has to a "public short thesis": diffuse sell-side skepticism rather than a named, evidence-backed campaign. It affects the setup only mildly — a cautious book leaves room for positive surprise on a clean Consumer Hearing exit or a China CI stabilization, but there is no crowded short to squeeze and no forced-cover fuel.

Evidence quality

Source: short-interest data staging manifest (source classes as staged) and Sonova annual-report disclosures cited above.

Net assessment for the PM. Positioning tells you nothing actionable here — treat SOON as a name with no short signal rather than a lightly-shorted one. The real risk register is the disclosed one: a Consumer Hearing divestment being executed under a strategic review, a China Cochlear Implants headwind, and a cautious sell-side. None of these is a credible forensic short thesis; each is a well-telegraphed operating question with the underlying franchise still growing in local currencies. Size and risk controls should key off the divestiture and China catalysts, not off short interest.